Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ripasudil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 13/20 | 1.00 |
| ▸ | ROCK1 known ✓ | Q13464 | 12/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 4/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | MARK3 | P27448 | 2/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 1.00 |
| ▸ | PKN2 | Q16513 | 2/20 | 1.00 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | MAP2K3 | P46734 | 1/20 | 1.00 |
| ▸ | CDK9 | P50750 | 1/20 | 1.00 |
| ▸ | PRKAG1 | P54619 | 1/20 | 1.00 |
| ▸ | PKN1 | Q16512 | 1/20 | 1.00 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 1.00 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 1.00 |
| ▸ | PRKACA | P17612 | 4/20 | 0.81 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.81 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ripasudil SCHEMBL31542 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL29356679 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL4897040 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL4897028 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL3081946 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL29404703 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL31419771 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL20557243 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL22497129 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL29365413 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1PRKCDPLK4MARK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025224050-A1 | METHODS OF TREATMENT OF PATIENTS SUFFERING FROM HYPOMELANOSIS OF ITO | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-10-30 | — | — | WO | disclosed |
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU (ES) | 2025-10-09 | — | — | US | disclosed |
| EP-4338751-B1 | COMBINATION OF SEPETAPROST AND NETARSUDIL FOR USE IN THE PROPHYLAXIS OR TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION | SANTEN PHARMACEUTICAL CO LTD (JP) | 2025-09-03 | — | — | EP | disclosed |
| US-12201602-B2 | Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2025-01-21 | — | — | US | disclosed |
| EP-4338751-A2 | MEDICAMENT COMPRISING COMBINATION OF SEPETAPROST AND RHO-ASSOCIATED COILED-COIL CONTAINING PROTEIN KINASE INHIBITOR | Santen Pharmaceutical Co., Ltd. (JP) | 2024-03-20 | — | — | EP | disclosed |
| EP-3730138-B1 | COMBINATION OF SEPETAPROST AND RIPASUDIL FOR USE IN THE PROPHYLAXIS OR TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION | SANTEN PHARMACEUTICAL CO LTD (JP) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023199010-A1 | TREATMENT OF MUSCLE FIBROSIS | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2023-10-19 | — | — | WO | disclosed |
| US-20220387372-A1 | MEDICAMENT COMPRISING COMBINATION OF SEPETAPROST AND RHO-ASSOCIATED COILED-COIL CONTAINING PROTEIN KINASE INHIBITOR | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2022-12-08 | — | — | US | disclosed |
| US-11446273-B2 | Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2022-09-20 | — | — | US | disclosed |
| US-20210106569-A1 | OMIDENEPAG COMBINATION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2021-04-15 | — | — | US | disclosed |
| EP-3231429-A1 | NOVEL AQUEOUS COMPOSITION | Kowa Company, Ltd. (JP) | 2017-10-18 | — | — | EP | disclosed |
| EP-3231431-A1 | AQUEOUS COMPOSITION | Kowa Company, Ltd. (JP) | 2017-10-18 | — | — | EP | disclosed |
| US-9540344-B2 | Production method for isoquinoline derivatives and salts thereof | KOWA CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9045460-B2 | Production method for isoquinoline derivatives and salts thereof | KOWA CO., LTD. (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20150087824-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | KOWA CO., LTD. (JP) | 2015-03-26 | — | — | US | disclosed |
| EP-2818463-A1 | Production method of 1,4-diazepane derivatives | Kowa Co., Ltd. (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-2610252-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | Kowa Co., Ltd. (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130144054-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | KOWA CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| JP-2007153891-A | MEDICINE FOR SUPPRESSING CHRONIC PROGRESSIVE RENAL DISORDER | KOWA CO | 2007-06-21 | — | — | JP | disclosed |
| EP-1074545-A1 | ISOQUINOLINESULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Hidaka, Hiroyoshi (JP) | 2001-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130144054-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | NOS2, NOS3, NOS1 | ROCK2 59/4885ROCK1 95/4885PRKCD 2704/4885 |
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | RHOA, MYLK2, MYLK | ROCK2 5/4885ROCK1 4/4885PRKCD 553/4885 |
| US-20220387372-A1 | MEDICAMENT COMPRISING COMBINATION OF SEPETAPROST AND RHO-ASSOCIATED COILED-COIL CONTAINING PROTEIN KINASE INHIBITOR | CIT, ROCK1, ROCK2 | ROCK2 3/4885ROCK1 2/4885PRKCD 282/4885 |
| US-12201602-B2 | Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor | CIT, ROCK1, ROCK2 | ROCK2 3/4885ROCK1 2/4885PRKCD 282/4885 |
| US-11446273-B2 | Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor | CIT, ROCK1, ROCK2 | ROCK2 3/4885ROCK1 2/4885PRKCD 282/4885 |
| US-20210106569-A1 | OMIDENEPAG COMBINATION | PTGIR, PDE6G, PDE3A | ROCK2 30/4885ROCK1 28/4885PRKCD 1802/4885 |
| US-20150087824-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | NOS2, NOS3, NOS1 | ROCK2 59/4885ROCK1 95/4885PRKCD 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.